Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients

JACEK PRZEMYSLAW GRABOWSKI, ROLF RICHTER, HANNAH RITTMEISTER, RADOSLAV CHEKEROV, HANNAH WOOPEN and JALID SEHOULI
Anticancer Research October 2018, 38 (10) 5853-5858; DOI: https://doi.org/10.21873/anticanres.12927
JACEK PRZEMYSLAW GRABOWSKI
1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
2North Eastern German Society of Gynecologic Oncology (NOGGO), Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jacek.grabowski@charite.de
ROLF RICHTER
1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANNAH RITTMEISTER
1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
2North Eastern German Society of Gynecologic Oncology (NOGGO), Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RADOSLAV CHEKEROV
1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
2North Eastern German Society of Gynecologic Oncology (NOGGO), Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANNAH WOOPEN
1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
2North Eastern German Society of Gynecologic Oncology (NOGGO), Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JALID SEHOULI
1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
2North Eastern German Society of Gynecologic Oncology (NOGGO), Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 38 no. 10 5853-5858
DOI 
https://doi.org/10.21873/anticanres.12927
PubMed 
30275210

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received August 19, 2018
  • Revision received September 1, 2018
  • Accepted September 4, 2018
  • Published online October 1, 2018.

Copyright & Usage 
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. JACEK PRZEMYSLAW GRABOWSKI1,2⇑,
  2. ROLF RICHTER1,
  3. HANNAH RITTMEISTER1,2,
  4. RADOSLAV CHEKEROV1,2,
  5. HANNAH WOOPEN1,2 and
  6. JALID SEHOULI1,2
  1. 1European Competence Center for Ovarian Cancer (EKZE), Department of Gynecology, Campus Virchow Klinikum, Charité – University Medicine of Berlin, Berlin, Germany
  2. 2North Eastern German Society of Gynecologic Oncology (NOGGO), Berlin, Germany
  1. Correspondence to: Dr. med. Jacek Grabowski, Department of Gynecology, European Competence, Center for Ovarian Cancer, Charité Comprehensive Cancer Center, Charité-University Medicine of Berlin, Augustenburger Platz 1,13353 Berlin, Germany. Tel: +49 30450664355, e-mail: jacek.grabowski{at}charite.de
View Full Text

Cited By...

  • 8 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (10)
Anticancer Research
Vol. 38, Issue 10
October 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients
JACEK PRZEMYSLAW GRABOWSKI, ROLF RICHTER, HANNAH RITTMEISTER, RADOSLAV CHEKEROV, HANNAH WOOPEN, JALID SEHOULI
Anticancer Research Oct 2018, 38 (10) 5853-5858; DOI: 10.21873/anticanres.12927

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients
JACEK PRZEMYSLAW GRABOWSKI, ROLF RICHTER, HANNAH RITTMEISTER, RADOSLAV CHEKEROV, HANNAH WOOPEN, JALID SEHOULI
Anticancer Research Oct 2018, 38 (10) 5853-5858; DOI: 10.21873/anticanres.12927
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Ovarian cancer
  • BMI
  • chemotherapy
  • toxicity
  • underweight
  • overweight
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire